Before anything clinical happens, there is a quieter problem to solve: the question of ketamine safety: contraindications, screening and red flags looks straightforward until you try to answer it with real numbers. This guide sets out what is actually established, what varies between providers, and what to establish before committing to anything, written as continuous explanation rather than a checklist, because the reasoning is what transfers to your own situation.
The difficulty facing someone comparing options in the United States is not a shortage of information but an excess of the promotional kind. Anyone comparing the United States programmes will find this decisive: distance is a clinical variable in a treatment requiring six visits in three weeks, which is exactly why remote components deserve serious consideration rather than dismissal. The logistics of an induction course are what quietly determine whether people finish treatment or abandon it partway through. That is as true in the United States as anywhere else in the country. Antagonism at the N-methyl-D-aspartate receptor appears to trigger a downstream cascade involving brain-derived neurotrophic factor and increased synaptic connectivity in mood-regulating regions. Response, where it occurs, is frequently not permanent, and many people move onto maintenance sessions spaced every two to six weeks. Patients researching the United States providers run into this constantly.
The mechanism is where ketamine departs from the antidepressants most people have already tried. Conventional selective serotonin reuptake inhibitors work primarily on monoamine systems and typically need four to six weeks before any effect is assessable. Ketamine acts on the glutamate system, principally as an antagonist at the N-methyl-D-aspartate receptor, and the downstream cascade it appears to trigger involves a surge in brain-derived neurotrophic factor and a measurable increase in synaptic connections in regions associated with mood regulation. Researchers describe this as a window of heightened neuroplasticity. The clinically useful framing is that ketamine may open a period during which the brain is more amenable to change, which is precisely why the therapeutic work done around the infusion matters as much as the infusion.
Why this question is harder than it should be
That holds in the United States as it does everywhere: nausea is common enough that many programmes give an antiemetic pre-emptively rather than waiting to see. Anyone searching for treatment in the United States meets the same wall of interchangeable clinic websites, all promising personalised care and none explaining what that means operationally. Coordination with an existing prescriber is a marker of considered practice, even though it slows the path to a first appointment. For anyone weighing options in the United States, appointment timing decides whether a course is compatible with employment, which is why the availability of early or late slots is more consequential than it sounds. Cost is the constraint that settles the question for a large share of people, which makes the reluctance to publish prices worth noticing. The the United States listings on this page are organised so that this is checkable rather than assumed. Applied to the United States, the point is this: preparation before the first session matters for the same reason: people who know in advance what the dissociative period feels like generally find it far less alarming.
What follows applies to the United States and to every other market, and it is the part worth reading slowly. The setting is not incidental decoration. Trial protocols were run in monitored medical environments, and the structural elements of those environments are part of what makes the treatment defensible: a clinician credentialed to manage sedation present in the building, continuous monitoring of blood pressure, heart rate and oxygen saturation, resuscitation equipment available, and a defined plan for what happens if someone becomes acutely distressed. A comfortable recliner and dim lighting are pleasant. They are not a substitute for any of the preceding items, and a tour that emphasises the former while being vague about the latter has answered a question you did not ask.
Safety, screening and the limits of the evidence
The headline per-session price usually excludes the consultation, any separately billed psychiatric evaluation, integration therapy and the maintenance sessions that follow. Nothing about the United States changes that. Advertising routinely blurs the line between approved esketamine and off-label generic ketamine, and the distinction carries real consequences for coverage. Dosing for mood indications sits far below anaesthetic levels, typically calculated near 0.5 milligrams per kilogram of body weight and delivered slowly across about forty minutes. It is worth carrying that into every conversation with a the United States provider. Comparing programmes in the United States is difficult because the variables that decide quality are rarely the ones displayed on a homepage. Pairing sessions with structured psychological support follows directly from the mechanism, which makes its absence a substantive gap rather than a stylistic one. It is the first thing to establish about any the United States programme.
A standard induction course in most American clinics runs to six sessions delivered over two to three weeks, though the number is a convention inherited from early trial protocols rather than a figure settled by comparative research. Some people are offered four; some programmes run to eight. What happens after induction is the genuinely unresolved part of the field. Response, where it occurs, is often not permanent, and many patients move onto a maintenance schedule of a single session every two to six weeks. Any clinic that presents six infusions as a complete and finished course without discussing what maintenance might look like, and what it might cost over a year, is describing half the treatment.
What to do next
The part worth underlining is that search results for ketamine treatment in the United States return a remarkably uniform set of pages, which makes genuine comparison harder rather than easier. Screening should cover cardiovascular history, personal and family history of psychosis or bipolar disorder, hepatic function, substance use history and current medications. The population the trial evidence covers is narrower than the advertising implies, concentrating on adults who have not responded to at least two adequate antidepressant trials. Read against the the United States market, commercial insurance seldom reimburses off-label intravenous administration, though the associated psychiatric evaluation is sometimes billable and worth asking about specifically.
The background that makes the United States listings interpretable is this. Ketamine is a Schedule III controlled substance in the United States, and that legal status shapes the entire delivery landscape. It means the drug carries a recognised potential for misuse and dependence. Legitimate programmes respond to that with structural safeguards rather than reassurance: doses administered on site and observed, no take-home supply of injectable product, defined session intervals, and screening that takes substance use history seriously rather than treating it as a formality. A programme willing to escalate frequency on request, or to ship product without meaningful assessment, has removed the guardrails that make the risk manageable.
Money, timing and the logistics people underestimate
In the United States the same rule applies: ketamine is a Schedule III controlled substance, which formally recognises a potential for misuse and shapes how responsible programmes are structured. The gap between anaesthetic and psychiatric dosing is large enough that describing them as the same treatment obscures more than it explains. It is worth carrying that into every conversation with a the United States provider. The practical difference is that esketamine is approved and more often insurable but less flexible, while intravenous ketamine is off-label, usually self-funded and more adjustable. The useful test for a remote programme is which components happen remotely and which require a monitored setting, and whether the answer is clear. Acting on a different receptor system explains both the speed of onset and why the treatment sometimes helps people whom other antidepressants have not. That is as true in the United States as anywhere else in the country.
The the United States comparison only becomes useful once this is clear. Side effects during a session are common, usually transient, and worth knowing about in advance rather than discovering in the chair. Dissociation is the one people ask about most: a sense of distance from the body, altered perception of time, sometimes visual distortion. For most people it peaks partway through the infusion and resolves within twenty to thirty minutes of the drip finishing. Nausea is frequent enough that many clinics give an antiemetic pre-emptively. Blood pressure and heart rate typically rise modestly during administration, which is the reason continuous monitoring is standard and the reason uncontrolled hypertension is treated as a serious caution. Headache, dizziness and a period of grogginess afterwards are ordinary. Driving is prohibited for the rest of the day without exception.
The underlying facts, stated once and clearly
The phrase treatment-resistant carries a specific meaning, and it only applies after documented trials at appropriate doses and durations. A separate line of research has examined rapid reduction in suicidal ideation specifically, which is a distinct question from sustained treatment of depression. Nothing about the United States changes that. Read against the the United States market, ketamine work sits between psychiatric assessment and sedation management, and clinicians arrive at it from either side with correspondingly different instincts. Each session occupies roughly two hours on site once administration, monitoring and recovery are counted, which is longer than most people budget for. For anyone whose decision turns on cost, asking whether a provider offers esketamine as well as intravenous administration is among the higher-value questions available. Continuous monitoring of blood pressure, heart rate and oxygen saturation is the baseline, because subanaesthetic dosing reliably produces a modest rise in the first two.
The the United States comparison only becomes useful once this is clear. Cost is the constraint that decides the matter for a large share of people, and the numbers are rarely posted plainly. A single intravenous infusion in the United States commonly falls somewhere between four hundred and eight hundred dollars, which puts a six-session induction in the range of roughly two and a half to five thousand dollars before any maintenance. Commercial insurance seldom reimburses off-label intravenous administration, though the associated psychiatric evaluation is sometimes billable. Esketamine is a different story, since an approved indication makes coverage plausible, subject to prior authorisation and documented failure of prior treatments. Before committing to anything, it is worth asking for the total cost of the induction course, the cost of a maintenance session, whether the consultation is billed separately, and what happens financially if treatment is stopped partway through.
Putting this to use
That holds in the United States as it does everywhere: a standard induction runs to six sessions across two to three weeks, a figure inherited from early trial protocols rather than settled by comparative research. Legitimate programmes respond to the abuse potential with structure rather than reassurance: observed administration, no take-home injectable supply and defined session intervals. The subanaesthetic dose used in this work is a fraction of the surgical dose, which is why the person stays awake, breathing independently and able to communicate. The mechanism matters practically because it implies the days after a session may be unusually receptive to therapeutic work. Esketamine, sold as Spravato, holds FDA approval for treatment-resistant depression in adults alongside an oral antidepressant, which puts it in a different regulatory category from generic infusions. It is the first thing to establish about any the United States programme.
The point of laying all this out is not to argue for or against treatment. It is to make sure that whichever way the decision goes, it is made with the real numbers and the real caveats rather than the marketing version.
This page is general information, not medical advice, and no directory can assess whether a treatment is appropriate for an individual. Ketamine is a controlled substance with genuine risks, and its use for mood disorders is off-label apart from esketamine, which holds FDA approval for treatment-resistant depression under a restricted programme. Decisions about treatment should be made with a qualified clinician who knows your full history. If you are in crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988 in the United States, or go to your nearest emergency department.